I have put out what I think revenue and Profits will be this year and in 2024 SAR. So I may be wrong but that gives me a very good foundation to guess and make decisions. Since I know how I calculated my numbers I will be aware quickly if something starts to change that will alter the results. Now UBS put out some numbers. Personally I think they are high for FY 2023 0.34 a share and low for FY 2024 at .05 a share. NdPr would have to drop a loot lower or expenses increase for 5 cents in 2024 to happen.
So why don't you look again at UBS Post #: 68292168. and do one of two things. either show some math why at NEXT rates 1800 T a Q and current prices why you think profits will be better. Or explain why with these earnings stock will not go down. Just for you info, earnings in FY 2022 were AU$ 571M or 0.63 a share. UBS is saying 0.34 about half. Show where UBS is wrong or why that will not cause stock to drop, to back up your statement. I sincerely doubt you can do either.
As always you say things off the top of your head Neither do you without thinking at all or doing any research. Makes your contributions worth not much.Typical response . If you cannot show why ideas are wrong fall back on insulting the poster to cover your lack of knowledge.
- Forums
- ASX - By Stock
- LYC
- Ann: Update on Kalgoorlie
Ann: Update on Kalgoorlie, page-34
Featured News
Add LYC (ASX) to my watchlist
(20min delay)
|
|||||
Last
$7.82 |
Change
-0.060(0.76%) |
Mkt cap ! $7.281B |
Open | High | Low | Value | Volume |
$7.79 | $7.85 | $7.70 | $4.026M | 516.9K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
8 | 2781 | $7.82 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$7.83 | 2691 | 10 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
15 | 2588 | 7.800 |
22 | 9061 | 7.790 |
15 | 6540 | 7.780 |
16 | 18206 | 7.770 |
10 | 8428 | 7.760 |
Price($) | Vol. | No. |
---|---|---|
7.810 | 5117 | 24 |
7.820 | 15992 | 15 |
7.830 | 9464 | 12 |
7.840 | 14092 | 10 |
7.850 | 6341 | 9 |
Last trade - 11.53am 12/11/2024 (20 minute delay) ? |
Featured News
LYC (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Michael Thurn, CEO & MD
Michael Thurn
CEO & MD
Previous Video
Next Video
SPONSORED BY The Market Online